Status of tumor markers in epithelial ovarian cancer has there been any progress? A review

被引:45
作者
Husseinzadeh, Nader [1 ]
机构
[1] Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Cincinnati, OH 45267 USA
关键词
Epithelial ovarian cancer; Screening ovarian tumor markers; C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; SERUM CA-125 LEVELS; EARLY-STAGE; PROTEOMIC PATTERNS; PROGNOSTIC-FACTOR; BIOMARKERS; EXPRESSION; MULTIPLE; IDENTIFICATION;
D O I
10.1016/j.ygyno.2010.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim is to present an overview of tumor markers other than CA-125 that have been proposed for use in the diagnosis of epithelial ovarian cancer and explore molecular studies which have been used to identify genomic and proteomic changes associated with this malignancy for possible future development of more sensitive tumor markers. Methods. A Medline search was conducted to review published articles from American and European studies from 1990 to 2010, related to tumor markers for ovarian cancer. Different methods such as genomic, proteomic and transcriptional profiling were used to identify new tumor markers for clinical use. Results. A few of the newer tumor markers alone have demonstrated equal or slightly higher sensitivity to CA-125. Improved sensitivity and specificity have been reported using these new markers combined with CA-125. Conclusion. Addition of new tumor markers as a compliment to CA-125 were associated with higher sensitivity and detection rates than either marker alone. However, the low prevalence of ovarian cancer necessitates a higher level of sensitivity and specificity that has still not been achieved if these biomarkers are used for diagnosis and monitoring the disease progress as a result of low positive predictive value. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 64 条
  • [11] Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer
    Brown, A.
    Miller, C.
    Robison, K.
    Somers, E.
    Allard, J.
    Granai, C. O.
    Skates, S.
    Bast, R. C., Jr.
    Moore, R. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [12] Cooper BC, 2002, CLIN CANCER RES, V8, P3193
  • [13] DEODHAR SD, 1989, CLEV CLIN J MED, V56, P126
  • [14] Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems
    Diamandis, EP
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (05): : 353 - 356
  • [15] Diamandis EP, 2002, CLIN CHEM, V48, P1198
  • [16] Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas
    Drapkin, R
    von Horsten, HH
    Lin, YF
    Mok, SC
    Crum, CP
    Welch, WR
    Hecht, JL
    [J]. CANCER RESEARCH, 2005, 65 (06) : 2162 - 2169
  • [17] EINHORN N, 1992, OBSTET GYNECOL, V80, P14
  • [18] Moderate progress for ovarian cancer in the last 20 years:: prolongation of survival, but no improvement in the cure rate
    Engel, J
    Eckel, R
    Schubert-Fritschle, G
    Kerr, J
    Kuhn, W
    Diebold, J
    Kimmig, R
    Rehbock, J
    Hölzel, D
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (18) : 2435 - 2445
  • [19] Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339
  • [20] Vascular endothelial growth factor localization in human ovary and fallopian tubes: Possible role in reproductive function and ovarian cyst formation
    Gordon, JD
    Mesiano, S
    Zaloudek, CJ
    Jaffe, RB
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (01) : 353 - 359